Preston C. Sprenkle, MD, presented “Update of Changes in the Early Detection of Prostate Cancer NCCN Guidelines 2024” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Sprenkle, Preston C. “Update of Changes in the Early Detection of Prostate Cancer NCCN Guidelines 2024.” October 8, 2024. Accessed Dec 2024. https://grandroundsinurology.com/update-of-changes-in-the-early-detection-of-prostate-cancer-nccn-guidelines-2024/
Update of Changes in the Early Detection of Prostate Cancer NCCN Guidelines 2024 – Summary
Preston C. Sprenkle, MD, Associate Professor of Urology at Yale University, delivers a comprehensive update on the 2024 National Comprehensive Cancer Network (NCCN) guidelines for early detection of prostate cancer.
In this 9-minute presentation, Dr. Sprenkle highlights the importance of early detection in identifying aggressive cancers while avoiding overtreatment of indolent disease, with shared decision-making and individualized risk assessment remaining central to guiding screening and treatment decisions. Refinements include clearer recommendations for younger patients with low PSA levels and adjusted screening intervals for men over 75. Genetic risk assessment and counseling are emphasized.
Sprenkle shares that the guidelines now recognize MRI as the standard of care for pre-biopsy evaluation. High-quality MRI imaging and expert interpretation are underscored to address variability in diagnostic practices. Systematic and MRI-targeted biopsies are preferred for improved accuracy in cancer detection. Dr. Frankel underscores the importance of integrating advanced imaging and equitable access to care to transform prostate cancer outcomes.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Preston C. Sprenkle, MD, is an Associate Professor of Urology at Yale University School of Medicine in New Haven, Connecticut. He also serves as Director of the Urology Research Fellowship and Urologic Oncology Clinical Fellowship Program at Yale, and as Division Chief of Urology in the VA Connecticut Healthcare System. Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device, and he is also a pioneer in focal therapy. In his practice, Dr. Sprenkle believes in working with patients to come up with individualized treatment plans to minimize the impact of prostate cancer diagnosis and treatment on their health and quality of life. His research focuses on biomarkers for prostate and kidney cancer, including the biomarker NGAL for acute kidney injury in surgical patients.
